Dr. Olsson on Differences Between LHRH Agonists and Antagonists in Prostate Cancer

Carl Olsson, MD
Published Online: Thursday, Jan 19, 2017



Carl Olsson, MD, Integrated Medical Professionals, compares the efficacy of LHRH agonists with antagonists, which are commonly used to treat patients with prostate cancer.

The use of the LHRH analog has been around for a long time, Olsson explains. To think about the best way to develop an agent, it would be to develop an antagonist versus an agonist, he adds. This is because the majority of drugs are agonists. Though they are effective and lower testosterone, they also accelerate the testosterone first. The best way to do this would be through drug management in order to develop an antagonist at the outset. That was very different biochemically, which is why researchers dealt with agonists primarily.

There was 1 antagonist that did have efficacy, but the side effect profile was too high. There is a second antagonist, he adds, which is showing promise in the prostate cancer field.


Carl Olsson, MD, Integrated Medical Professionals, compares the efficacy of LHRH agonists with antagonists, which are commonly used to treat patients with prostate cancer.

The use of the LHRH analog has been around for a long time, Olsson explains. To think about the best way to develop an agent, it would be to develop an antagonist versus an agonist, he adds. This is because the majority of drugs are agonists. Though they are effective and lower testosterone, they also accelerate the testosterone first. The best way to do this would be through drug management in order to develop an antagonist at the outset. That was very different biochemically, which is why researchers dealt with agonists primarily.

There was 1 antagonist that did have efficacy, but the side effect profile was too high. There is a second antagonist, he adds, which is showing promise in the prostate cancer field.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New York GU™: 9th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary MalignanciesMay 27, 20171.5
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Genitourinary CancersJul 28, 20171.5
Publication Bottom Border
Border Publication